Eastern Food Allergy & Comorbidity Conference 2023

January 5, 2023 to January 8, 2023

The 2023 EFACC activity will provide conference attendees with knowledge regarding novel food allergy developments and the expanding therapeutic armamentarium in the field of allergy, asthma and immunology, particularly as it relates to food allergy and associated allergic comorbidities. In addition to a didactic review of relevant guidelines and recent clinical studies, the format will incorporate problem-based learning (PBL), uniquely designed to interface with lectures in context to the core learning objectives relevant to the cases. By means of active discussion, learners will be challenged to formulate and justify medical decision-making concerning diagnostic and treatment strategies for patients food allergy and comorbid allergic diseases. Topics of discussion will include food allergy prevention, food allergy immunotherapy, asthma, atopic dermatitis, eosinophilic esophagitis and shared decision making.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunoolgy and Eastern Allergy Conference (EAC). The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 19.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 19.25 contact hours. 

Target Audience

Physicians and allied health staff providing care for food allergies.

Learning Objectives

At the conclusion of the activity learners should be ablet to:

  1. Initiate an appropriate evaluation and treatment strategy for eosinophilic esophagitis based on history, endoscopy, biopsy, and shared decision making.
  2. Discuss the risks and benefits of oral peanut challenges and peanut desensitization via immunotherapy.
  3. Discuss quality of life and psychological issues associated with food allergy.
  4. Explain the role of nutrition in the management of food allergy.
  5. Diagnose and treat comorbidities of food allergy including atopic dermatitis and asthma.
  6. Incorporate shared decision making into food allergy management.
  7. Appropriately treat anaphylaxis attributable to food allergy.
  8. Provide evidence-based advice regarding food allergy prevention to parents of infants at high risk for developing food allergy.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 19.25 AMA PRA Category 1 Credit™
  • 19.25 Attendance
  • 19.25 CBRN
Course opens: 
01/05/2023
Course expires: 
01/04/2026
Event starts: 
01/05/2023 - 2:00pm CST
Event ends: 
01/08/2023 - 12:00pm CST
Add to calendar: 
Rating: 
5

 

Eastern Food Allergy & Comorbidity Conference Meeting Program
January 5-8, 2023

Thursday, January 5, 2023

2:00-2:30 Quality of life and psychological issues associated with food allergy, Justin Greiwe, MD

2:30-3:00 EoE: How and why? - Fred Dan Atkins, MD

3:00-4:15 - PBL: An 18-year-old male with dysphagia, asthma, atopic dermatitis and seasonal rhinitis
Ray Davis, MD, Don Bukstein, MD, Dana Wallace, MD Ellen Sher, MD, Russell Settipane, MD

4:15 -4:30 Break

4:30-5:00 EoE management debate: Who gets diet? - Fred Dan Atkins, MD

5:00-5:30 EoE management debate: Who gets nonbiologic medical therapy? - Ellen Sher, MD

5:30-6:00 EoE management debate: Who gets biologics? - Mirna Chehade, MD

6:00-6:15 EoE shared decision making - Don Bukstein, MD

6:15 -6:30 Panel Discussion: Q & A

Adjourn

Friday, January 6, 2023

7:45 -8:15 FPIES: Beyond the guidelines - Anna Nowak-Wegrzyn, MD

8:15 - 8:45 The role of nutrition in the management of food allergy, Carina Venter, PhD, RD, Marion Groetcb, MS, RDN

8:45-10:00 PBL: A 4-year-old male with atopic dermatitis, asthma and multiple food sensitivities
Ray Davis, MD, Don Bukstein, MD, Maeve O'Connor, MD Richard Wasserman, MD, Russell Settipane, MD

10:00 - 10:45 Coffee Break: Visit exhibits and posters

10:45 - 11:05 Peanut allergy diagnosis: A 2020 practice parameter update - Dana Wallace, MD

11:05 - 11:25 Food Challenges: Patient selection, predictors, component testing and decision points, Julie Wang, MD

11:25 - 11:45 Shared decision making and communicating risk in food allergy, Marcus Shaker, MD

11:45 - 12:10 Atopic dermatitis and food allergy - Amber Pepper, MD

12:10- 12:25 Panel Discussion: Q & A

1:20-1:45 Asthma and food allergy - David Stukus, MD

1:45-1:50 Panel Discussion: Q & A

1:50-3:00 Food challenge panel discussion:
Implementation/Office set up/Safety - Doug Mack, MD
Establishing the goals/End points - Richard Wasserman, MD
Patient selection - Julie Wang, MD
Protocols/Mitigating risk - Marcus Shaker, MD
Pearls and pitfalls - Katherine Anagnostou, MD

Adjourn

Saturday, January 7, 2023

7:45-8:15 Misinformation and the role of social media in food allergy - David Stukus, MD

8:15-9:20 PBL: An 8-year-old male with peanut allergy
Ray Davis, MD, Don Bukstein, MD, Dana Wallace, MD Sally Bailey, MD, Russell Settipane, MD

9:20-10:00 Coffee Break: Visit exhibits and posters

10:00 - 10:20 Epicutaneous peanut immunotherapy, Julie Wang, MD

10:20 - 10:40 FDA approved peanut OIT - Katherine Anagnostou, MD

10:40- 11:00 Non-FDA approved peanut OIT and SLIT - Richard Wasserman, MD

11:00 - 11:20 Peanut allergy SDM - Don Bukstein, MD

11:20 - 11:30 Panel Discussion: Q & A

11:30- 12:002020 Anaphylaxis practice parameter update and beyond, Marcus Shaker, MD

1:00-2:15 OIT panel discussion:

Establishing the goals - Doug Mack, MD
Implementation/Office set up/Safety - Julie Wang, MD
Patient selection/Predictors of success - Katherine Anagnostou, MD
Dose escalation - Marcus Shaker, MD
Maintenance dosing - Richard Wasserman, MD

2:15-2:45 Mechanisms of desensitization with OIT/EPIT - Joseph Bellanti, MD

2:45-3:00 Panel Discussion: Q & A

Adjourn

Sunday, January 8, 2023

8:15 - 8:45 New insights in hidden food allergies - Sami Bahna, MD

8:45 -9:15 The role of the microbiome in food allergy - Rima Rachid, MD

9:15-9:45 Infant food allergy prevention - Doug Mack, MD

9:45 - 10:15 Practical aspects of food allergy prevention - Carina Venter, PhD, RD, Marion Groetch, MS, RDN

10:15 - 10:45 Novel therapies in the treatment of food allergy - Rima Rachid, MD

10:45 - 11:15 Food allergy ladders: What's the evidence? - Doug Mack, MD

11:15 - 11:45 To the ED or not? That is the FA anaphylaxis management question - Anna Nowak-Wegrzyn, MD

11:45 - 12:00 Panel Discussion: Q & A

Adjourn

Disclosure Policy and Disclosures

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers).

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. 

All relevant financial relationships with ineligible companies have been mitigated.

The individuals listed below disclose the following financial relationships:

Katherine Anagnostou, MD, Speaker
Speaker: Aimmune Therapeutics
Researcher: Novartis, Aimmune Therapeutics:
Consultant: ALK
Advisor: DBV Technologies

Sally Bailey, MD, Planner
Consultant: ALK

Don Bukstein, MD, Speaker
Speaker: Regeneron, AstraZeneca

Mirna Chehade, MD, Speaker
Researcher: Regeneron, Allakos, Adare/Ellodi, AstraZeneca, Shire/Takeda,
Consultant: Regeneron, Allakos, Adare/Ellodi, AstraZeneca, Sanoli, Bristol Myers Squibb, Shire/Takeda, Phathom, Danone

William Corrao, MD, Planner, Moderator
Speaker - GSK, Boehringer lngelheim
 
Ray Davis, MD, Speaker, PBL Facilitator
Speaker: TEVA
Consultant: TEVA, Sanofi, Regeneron, Takeda

Justin Greiwe, MD, Speaker
Speaker: AstraZeneca, Sanofi Genzyme/Regeneron Advisor: AstraZeneca, Sanofi Genzyem/Regeneron

Doug Mack, MD, Speaker
Researcher: ALK-Abello, DBV, Consultant: Aimmune

Anna Nowak-Wegrzyn, MD, Speaker
Speaker: Nestle, Danone, Thermofisher Consultant: Nestle, Danone, Thermofisher
Advisor: Novartis, Acquisitive, Aimmune, ARS Pharma Researcher: Regeneron, DBV, Alladapt

Maeve O'Connor, MD, Planner
Speaker - Regeneron, AbbVie

Amber Pepper, MD, Speaker
Independent Contractor: Regeneron, Pfizer, Aimmune, Sanofi, Suzhou Connect, ARS Pharma, Takeda, lgGenix, Novartis, Stallergenes Greer, Alladapt

Rima Rachid, MD, Speaker
Independent Contractor: Novartis, Siolta Therapeutics Consultant: Novartis
Ownership Interest: Pareto Bio

Robert Settipane, MD, Planner
Independent Contractor: AstraZeneca, GSK, Regeneron, TEVA

Russell Settipane, MD, Planner, Speaker, Moderator, Reviewer
Speaker: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, GSK, Genentech, Regeneron, Sanofi, Takeda
Advisor: AbbVie, Aimmune, Pfizer, AstraZeneca, Boehringer Ingelheim, GSK, DBV Independent Contractor: AstraZeneca, GSK, TEVA, Regeneron,

Ellen Sher, MD, Speaker
Advisor: AstraZeneca, Aimmune, Novartis, Regeneron, Sanofi Genzyme Speaker: AstraZeneca, Aimmune, Novartis, Regeneron, Sanofi Genzyme
Researcher: AstraZeneca, Aimmune, Amgen, Novartis, Regeneron, Sanofi Genzyme Consultant: AstraZeneca, Aimmune, Novartis, Regeneron, Sanofi Genzyme

David Stukus, MD, Speaker
Consultant: ARS Pharmaceuticals, Kaleo, Novartis

Carina Venter, PhD, Speaker
Speaker: Danone, Reckitt, Nestle, Abbott Advisor: Reckitt, Nestle, Abbott
 
Dana Wallace, MD, Speaker, PBL Facilitator
Speaker: Bryn, Sanofi

Julie Wang, MD, Speaker
Researcher: Aimmune, DBV, Regeneron Consultant: Jubilant Hollister Stier

The following have no relevant financial relationships to disclose:

Dan Atkins, MD, Speaker
Sarni L Bahna, MD, Speaker
Joseph Bellanti, MD, Speaker
William Greisner III, MD, Planner, Moderator, Reviewer
Marion Groetch, MS, RDN, Speaker
Ginny Loiselle, Coordinator
Katelyn Loiselle, BSN, RN, Planner
Marcus Shaker, MD, Speaker
Michael Slaughter, MD, Planner
Richard Wasserman, MD, Speaker
Kelli Wilson, Planner

Available Credit

  • 19.25 AMA PRA Category 1 Credit™
  • 19.25 Attendance
  • 19.25 CBRN
Please login or create an account to take this course.